The Clinical Dementia Rating Scale stages how dementia affects thinking and daily function inside an Alzheimer's diagnostic workup. It describes severity, but it does not identify Alzheimer's disease by itself. Doctors use the score as functional context. They still confirm the cause with medical history, cognitive tests, scans, and amyloid or tau biomarker tests.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the six ratings capture
- Where staging fits in the workup
- Why biology must confirm the stage
- How stage plus amyloid status guides treatment
- What can shift a score
What the six ratings capture
Washington University developed the CDR to stage dementia across six domains. It rates memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. Ratings come from semi-structured interviews with the patient and a reliable informant, as Washington University Knight ADRC describes in its CDR scoring table. A global algorithm gives 0 for normal cognition and 0.5 for very mild or questionable dementia.
Scores of 1, 2, or 3 mean mild, moderate, or severe dementia. The result tracks overall impairment, not one specific disease. The CDR-Sum of Boxes adds the six domain scores into a 0-18 scale. Higher means worse cognition and function. A Springer CNS Drugs review notes that this finer scale makes small changes usable as trial endpoints.
Where staging fits in the workup
In a standard Alzheimer's workup, CDR-type staging sits alongside history, exams, and tests. Cognitive testing covers memory, problem-solving, attention, counting, and language. Labs plus MRI, CT, or PET look for other causes and brain changes, according to the National Institute on Aging in its diagnostic guide.
A visit often follows this order. The score then shows how test results relate to daily life. Bring notes about daily tasks, safety, driving, work, and mood. That detail helps the clinician match function to the other findings.
- Share history and daily changes with an informant present
- Complete memory, thinking, and language checks
- Get labs and MRI, CT, or PET as advised
- Discuss CSF or blood tests for amyloid and tau
Why biology must confirm the stage
The 2024 Alzheimer's Association Workgroup criteria define Alzheimer's biologically. One abnormal Core 1 amyloid or tau biomarker can establish it. The framework pairs biological stages A through D with clinical stages 1 through 6, from asymptomatic to severe dementia, as Jack and colleagues report in PubMed 38934362.
Symptoms alone are not diagnostic under that framework. NIA biomarker guidance and a Front Dementia summary of the 2024 criteria explain that a CDR score must join amyloid and tau evidence. No single cognitive test or biomarker alone diagnoses Alzheimer's.
How stage plus amyloid status guides treatment
This pairing affects treatment choice. Lecanemab's confirmatory CLARITY-AD trial enrolled people with amyloid-confirmed mild cognitive impairment or mild dementia.
It showed CDR-SB worsening of 1.21 versus 1.66 on placebo, a difference of -0.45 at 18 months. That result supports starting only with confirmed amyloid pathology, according to FDA prescribing information 2026 in the FDA label. In practice, the clinician confirms amyloid, records the starting CDR-SB, and then tracks change over time.
What can shift a score
CDR scoring needs a trained rater and a knowledgeable informant. Non-Alzheimer's causes of impairment can also raise the score. A Clin Medicine and Research description and a 2024 fluctuation study note that scores can shift and need rechecking with medical, neurologic, and biomarker review.
Reduce noise by bringing the same informant to each visit. List new medicines, illness, poor sleep, pain, hearing loss, and mood changes. Ask when staging and biomarker checks should be repeated.
